CN116847874A - Dhodh抑制剂化合物在组合癌症疗法中的用途 - Google Patents

Dhodh抑制剂化合物在组合癌症疗法中的用途 Download PDF

Info

Publication number
CN116847874A
CN116847874A CN202180052749.9A CN202180052749A CN116847874A CN 116847874 A CN116847874 A CN 116847874A CN 202180052749 A CN202180052749 A CN 202180052749A CN 116847874 A CN116847874 A CN 116847874A
Authority
CN
China
Prior art keywords
lymphoma
compound
pharmaceutically acceptable
formula
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180052749.9A
Other languages
English (en)
Chinese (zh)
Inventor
J·科可
B·尼古拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of CN116847874A publication Critical patent/CN116847874A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180052749.9A 2020-08-27 2021-08-26 Dhodh抑制剂化合物在组合癌症疗法中的用途 Pending CN116847874A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063070984P 2020-08-27 2020-08-27
US63/070,984 2020-08-27
PCT/US2021/047778 WO2022047051A1 (en) 2020-08-27 2021-08-26 Use of a dhodh inhibitor compound in combination cancer therapy

Publications (1)

Publication Number Publication Date
CN116847874A true CN116847874A (zh) 2023-10-03

Family

ID=78000775

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180052749.9A Pending CN116847874A (zh) 2020-08-27 2021-08-26 Dhodh抑制剂化合物在组合癌症疗法中的用途

Country Status (9)

Country Link
US (1) US20230285365A1 (https=)
EP (1) EP4203950B1 (https=)
JP (1) JP7734742B2 (https=)
KR (1) KR20230078997A (https=)
CN (1) CN116847874A (https=)
BR (1) BR112023003493A2 (https=)
CA (1) CA3190511A1 (https=)
ES (1) ES3063941T3 (https=)
WO (1) WO2022047051A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211462T1 (hr) 2017-04-24 2021-12-24 Aurigene Discovery Technologies Limited Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze
TWI818954B (zh) 2018-02-20 2023-10-21 法商施維雅藥廠 三取代之苯并三唑衍生物的使用方法
JOP20210147A1 (ar) * 2018-12-21 2023-01-30 Les Laboratoires Servier Sas صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459184A (zh) * 2014-02-28 2017-02-22 詹森生物科技公司 与抗cd38抗体联用的组合疗法
US20180369206A1 (en) * 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
WO2019164794A1 (en) * 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
WO2020109625A1 (en) * 2018-11-30 2020-06-04 Fondazione Centro San Raffaele Combined treatment of primary central nervous system lymphoma
WO2020132471A1 (en) * 2018-12-21 2020-06-25 Agios Pharmaceuticals, Inc. Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57962B1 (sr) 2013-02-25 2019-01-31 Aurigene Discovery Tech Ltd Derivati trisupstituisanog benzotriazola kao inhibitori dihidroorotat oksigenaze
HRP20211462T1 (hr) * 2017-04-24 2021-12-24 Aurigene Discovery Technologies Limited Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459184A (zh) * 2014-02-28 2017-02-22 詹森生物科技公司 与抗cd38抗体联用的组合疗法
US20180369206A1 (en) * 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
WO2019164794A1 (en) * 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
WO2020109625A1 (en) * 2018-11-30 2020-06-04 Fondazione Centro San Raffaele Combined treatment of primary central nervous system lymphoma
WO2020132471A1 (en) * 2018-12-21 2020-06-25 Agios Pharmaceuticals, Inc. Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STRAUS, DJ等: ""Final results of phase II trial of doxorubicin HCI liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma"", 《ANNALS OF ONCOLOGY》, 26 November 2013 (2013-11-26), pages 1 - 6 *

Also Published As

Publication number Publication date
US20230285365A1 (en) 2023-09-14
WO2022047051A1 (en) 2022-03-03
JP7734742B2 (ja) 2025-09-05
KR20230078997A (ko) 2023-06-05
CA3190511A1 (en) 2022-03-03
EP4203950C0 (en) 2026-02-18
ES3063941T3 (en) 2026-04-21
EP4203950A1 (en) 2023-07-05
BR112023003493A2 (pt) 2023-04-11
JP2023540206A (ja) 2023-09-22
EP4203950B1 (en) 2026-02-18

Similar Documents

Publication Publication Date Title
CN116847874A (zh) Dhodh抑制剂化合物在组合癌症疗法中的用途
JP2016523858A (ja) がんを治療するためのｂｔｋ阻害剤とフルオロウラシルとの併用
EP3400942B1 (en) Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof
US20240058305A1 (en) Treatments with nirogacestat
WO2019109938A1 (zh) Parp抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途
US11951096B2 (en) Treatments with nirogacestat
US11419862B2 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
CN116406275A (zh) Dhodh抑制剂化合物在组合癌症疗法中的用途
US20100286038A1 (en) Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
AU2019263026B2 (en) Combinations for treating cancer
KR20240158972A (ko) 소세포 폐암의 치료 방법
EA049299B1 (ru) Применение соединения-ингибитора на основе dhodh в комбинированной терапии рака
KR20260048300A (ko) 종양 질환을 치료하기 위한 EGFR 키나제 억제제와 c-Met 키나제 억제제의 약물 조합
TW202515550A (zh) 三并環類抑制劑與抗癌劑在製備抗腫瘤藥物中的聯合應用
KR20250055565A (ko) 티로신 키나아제 억제제 보도바티닙을 사용하여 만성 골수성 백혈병을 치료하는 방법
CA3010654C (en) Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof
TW202315615A (zh) Pi3k抑制劑與btk抑制劑在製備治療淋巴瘤的藥物中的用途
AU2024304092A1 (en) Use of akt inhibitor in preparation of drug for preventing or treating breast cancer
HK40041700A (en) Combinations for treating cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination